Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025

Stock Information for Design Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Design Therapeutics Inc.

Design Therapeutics to Participate in Upcoming Investor Conferences
Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results
Design Therapeutics Appoints Justin Gover to Board of Directors
Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference
Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.